You are here

A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

Last updated on November 13, 2019

FOR MORE INFORMATION
Study Location
Miaoli County, , 351 Taiwan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
NCT00724919
Pfizer
Completed
A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Descriptive Information
Brief TitleA Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli
Official TitleAssociation of Antibiotic Utilization Measures and Control of Extended-Spectrum ?-Lactamases (ESBLs) (A Post-Intervention Surveillance Study)
Brief SummaryTo determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres
Detailed DescriptionThis is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study.
Study TypeObservational
Study DesignObservational Model: Cohort
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study Populationpatients admitted to ICU/burn unit
ConditionInfection
InterventionNot Provided
Study Groups/Cohorts1
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: July 25, 2008)
256
Original Actual EnrollmentSame as current
Actual Study Completion DateApril 2004
Actual Primary Completion DateApril 2004   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion

  1. All patients admitted or transferred to ICU/burn unit.
  2. Patients of either sex, 18 years of age or older. Exclusion

Patients were excluded if they had underlying conditions or diseases that were ultimately fatal within 48 hours

Sex/Gender
Sexes Eligible for Study:All
Ages18 Years and older   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesTaiwan
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00724919
Other Study ID Numbers0910X-101440
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyWyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study SponsorWyeth is now a wholly owned subsidiary of Pfizer
CollaboratorsNot Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS AccountWyeth is now a wholly owned subsidiary of Pfizer
Verification DateAugust 2008

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now